Xenikos

Name

Xenikos

Legal name

Xenikos B.V.

Website

https://xenikos.com

Company type

Private

Founded year

2009

Operating status

Closed

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industry

Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)

Keywords

• Immunotherapy drug development
• Anti-T-cell antibodies
• Graft-versus-host disease treatment
• Immune system reset therapy
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

Xenikos developed T-Guard®, an investigational immunotherapy combining two toxin-loaded anti-T-cell antibodies designed to safely and swiftly reset the body's immune system. The product was being developed to treat T-cell mediated diseases, with the lead indication being grade III/IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplantation, with potential applications in transplant-related rejection, solid-organ rejection, and severe autoimmune diseases.

Product overview

Xenikos was a biopharmaceutical company that developed T-Guard®, a combination of two toxin-loaded anti-T-cell antibodies. T-Guard® was designed as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company ceased operations following the discontinuation of its Phase 3 clinical trial in early 2023. Further development of T-Guard® is being explored for other clinical indications.

Differentiator

Problem solved

Functional benefit

Brands

• T-Guard®: A medicine currently under development that safely and swiftly 'resets' the body's immune system, showing potential in treating transplant-related rejection, acute graft-versus-host disease (aGVHD), solid-organ rejection, and severe autoimmune diseases.

Products and services

• T-Guard® Investigational immunotherapy combining two toxin-loaded anti-T-cell antibodies designed to safely and swiftly reset the body's immune system. Being developed for grade III/IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant, with potential applications in transplant-related rejection, solid-organ rejection, and severe autoimmune diseases.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• AbbVie: AbbVie commercializes ibrutinib (Imbruvica) for chronic GVHD. Comparable as a broad incumbent biopharma with approved therapies in the GVHD space.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals markets defibrotide (Defitelio) for hepatic veno-occlusive disease following stem cell transplant and has broader transplant-related commercial infrastructure. Comparable as a commercial-stage biopharma in the transplant/HSCT space.
• Takeda Pharmaceutical: Takeda is a global biopharma with a strong transplant and post-transplant complications portfolio (e.g., through the Shire acquisition). Comparable as a major biopharma with strategic interest in transplant immunology.
• Eli Lilly: Eli Lilly has a presence in transplant immunology and autoimmune disease, and olomorasib/baricitinib pipelines intersect with inflammatory disease biology. Comparable as a broad incumbent biopharma with interest in immune-mediated disease.

Direct peers

• Incyte: Incyte developed and commercialized ruxolitinib (Jakafi), the first FDA-approved therapy for steroid-refractory acute GVHD. It is the most directly competitive therapy to T-Guard's lead indication and represents the standard-of-care Xenikos would have targeted.
• Mesoblast: Mesoblast developed remestemcel-L (Ryoncil), an allogeneic mesenchymal stem cell therapy approved by FDA for pediatric steroid-refractory aGVHD. Comparable to Xenikos in targeting SR-aGVHD with a novel cell/biologic approach.
• Equillium: Equillium is developing itolizumab (EQ001), a monoclonal antibody targeting CD6, for acute GVHD and other immuno-inflammatory diseases. Comparable as a clinical-stage biotech developing immune-modulating biologics for transplant-related indications.
• Kadmon Holdings (acquired by Sanofi): Kadmon developed belumosudil (Rezurock), an FDA-approved ROCK2 inhibitor for chronic GVHD. Comparable as a developer of novel small-molecule/biologic therapies for graft-versus-host disease.
• Atara Biotherapeutics: Atara developed tabelecleucel (tab-cel), an allogeneic T-cell therapy for EBV-driven post-transplant lymphoproliferative disease. Comparable as a T-cell focused biopharma addressing post-transplant complications.

Emerging players

• MaaT Pharma: MaaT Pharma is developing microbiome-based therapies for acute GVHD and other immune conditions. Comparable as an emerging European biotech targeting steroid-refractory aGVHD with a novel immune-modulating approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/xenikos-b-v

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xenikos